Noxopharm Ltd. (AU:NOX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Limited has announced the issuance of A$2.1 million in convertible notes to sophisticated investors, aimed at providing funding for the company to pursue potential opportunities without immediate financial pressure. The notes come with a 12% interest rate and options for investors, plus an additional potential A$500,000 investment from the company’s chairman pending shareholder approval. This move is part of Noxopharm’s strategy to progress in developing novel cancer and inflammation treatments, as well as enhancing mRNA vaccine technology.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.